DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for malignant triton tumor — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMalignant triton tumor maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for malignant triton tumor is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
SS18 subunit of BAF chromatin remodeling complex (SS18) — SS18 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7VRB · 2.389 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
A 38-year-old woman with a malignant triton tumour in the nasal cavity was treated with wide surgical excision followed by radiation therapy. Her postoperative course was unremarkable, and follow-up at five years showed no evidence of disease. This is a single case report; no other patients were described, and no survival statistics or response rates beyond this one individual were given.
A separate case report analysed the transition from malignant schwannoma to malignant triton tumour in a patient with recurring cancers and a suspected familial predisposition. Loss of one Patched gene allele was found in the advanced triton tissue, but the retained allele had no exon or promoter mutations. In the first occurrence of triton tumour, protein levels at early cancer stages indicated a possible Patched response to Hedgehog-Patched pathway activation. In the recurring triton, Patched expression was several times lower than in control tissue, suggesting that haploinsufficiency was aided by silencing of the remaining allele, though its promoter was not hypermethylated. The authors noted that these findings may justify further investigation of the Hedgehog-Patched pathway in triton malignancies, especially given recent research on the therapeutic potential of the pathway. No drug was tested or mentioned in either abstract.
A third abstract describes a patient with myotonic dystrophy and a malignant proliferating trichilemmal tumour of the scrotum, which is a different disease from malignant triton tumour. That patient received only total excision due to hypoxaemia and hypercapnia from myotonic dystrophy, and had no evidence of recurrence for one year. This abstract is not relevant to malignant triton tumour.
What is still missing: prospective trials or even small case series with consistent treatment protocols, any drug intervention tested in malignant triton tumour, and patient stratification by genetic or molecular markers such as Patched pathway status. Funding for such studies and a trial design that can account for the extreme rarity of the disease remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Head & Neck · 2001 · 29 citations
Malignant triton tumor of the nasal cavity
AbstractBACKGROUND: Malignant triton tumor is usually an aggressive sarcoma consisting of a malignant schwannoma with rhabdomyoblastic differentiation. However, malignant triton tumor of the nasal cavity is very rare. METHODS: A case report of a 38-year-old woman with polypoid mass, which bled easily in the right nasal cavity, and nasal obstruction is presented with a review of the literature pertaining to this unusual case. RESULTS: The malignant triton tumor was treated with wide surgical excision followed by radiation therapy. Histopathological diagnosis of the malignant triton tumor was made on the surgical specimen. The patient's postoperative course was unremarkable, and follow-up at 5 years reveals no evidence of disease. CONCLUSIONS: A malignant triton tumor in the nasal cavity is a rare disease. Head and neck surgeons should recognize the possibility of malignant triton tumor occurring in the nasal cavity.
Oncology Reports · 1994 · 5 citations · open access
Hedgehog-Patched pathway aberrations in a malignant triton tumor case study
AbstractTransition from malignant schwannoma to malignant triton tumor is analyzed in a case report on a patient with recurring cancers and suspected familial predisposition. It is hypothesized that rhabdomyoblastic differentiation, which distinguishes triton from schwannoma, might be attributable to Hedgehog-Patched pathway malfunctioning. Loss of one Patched gene allele was found in the tissue of advanced triton, but the retained allele had no exon or promoter mutations. Protein levels at early cancer stages indicated possible Patched response to the pathway activation in the first occurrence of triton tumor. Later, in the recurring triton, Patched expression was several times lower than in the control tissue, suggesting that haploinsufficiency was aided by silencing of the remaining allele, although its promoter was not hypermethylated. These findings may justify further investigation of the Hedgehog-Patched pathway role in triton malignancies, especially because of the recent research on the therapeutical potential of the pathway.
A case of malignant proliferative trichilemmoma of the scrotum complicated with dystrophia myotonica.
AbstractA patient who has myotonic dystrophy and malignant proliferating trichilemmal tumor on his scrotum is repoted. In general, the treatment for malignant proliferating trichilemmal tumor is the same for squamous cell carcinoma. However, this patient was only received the total excision of tumor because of hypoxemia and hypercarcemia by myotonic dystrophy. Since the extirpation, there has been no evidence of recurrence for one year.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
